Key Takeaways
- Pete Pharma partners with Fagron to scale pharma 3D printing in the US and Canada
- The partnership aims to expand access to automated solid dosage form manufacturing for 503A and 503B compounding pharmacies
- The collaboration combines Fagron's commercial reach with Pete Pharma's 3D pharmaceutical printing platform, including the M3DIMAKER hardware and software infrastructure
- The goal is to accelerate adoption of next-generation pharmaceutical manufacturing and enable pharmacies to improve efficiency and deliver more differentiated therapies
Introduction to Pharma 3D Printing
Pharmaceutical 3D printing is a rapidly evolving field that enables the creation of customized medications with precise dosages and formulations. Pete Pharma, a pioneer in pharma 3D printing, has partnered with Fagron, a global leader in pharmaceutical compounding and personalized medicine, to scale up the adoption of this technology.
Partnership Details
Under the terms of the agreement, Fagron has been appointed as an exclusive reseller of Pete Pharma's 3D printing platform across the United States and Canada. The partnership will focus on expanding access to automated solid dosage form manufacturing for both 503A and 503B compounding pharmacies. The collaboration brings together the FABRx and Pete Pharma 3D pharmaceutical printing platform, including the M3DIMAKER hardware, software infrastructure, and delivery systems, with Fagron's extensive commercial reach and established relationships across the compounding industry.
Comparison of 3D Printing Platforms
| Feature | Pete Pharma's M3DIMAKER | Traditional Manufacturing |
|---|---|---|
| Dosage Form Flexibility | Immediate-release tablets, extended-release formulations, oral films, troches, water-dissolvable tablets, chewables, and suppositories | Limited to traditional tablet and capsule forms |
| Manufacturing Efficiency | Automated and scalable | Manual and labor-intensive |
| Regulatory Compliance | Compliant with 503A and 503B regulations | Variable compliance |
Benefits of the Partnership
The partnership between Pete Pharma and Fagron aims to accelerate the adoption of next-generation pharmaceutical manufacturing within pharmacies. By combining commercial reach with advanced manufacturing technology, the two organizations aim to enable pharmacies to improve efficiency, increase throughput, and deliver more differentiated therapies to patients. The goal is to modernize compounding through innovation, strategic partnerships, and scalable infrastructure.
Bottom Line
The partnership between Pete Pharma and Fagron marks a significant milestone in the evolution of pharma 3D printing. With the combined expertise and resources of these two industry leaders, the potential for widespread adoption of this technology is vast. As the pharmaceutical industry continues to shift towards more personalized and precise medication, the collaboration between Pete Pharma and Fagron is poised to play a key role in shaping the future of pharmaceutical manufacturing.